SNMMI

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear Cardiology (ASNC) released a new online course designed to provide cardiovascular and other nuclear medicine physicians with the knowledge needed to establish a culture of safety and quality in their nuclear imaging laboratories.
News | Nuclear Imaging
New ASNC/SNMMI Training Course Helps Physicians Meet U.S. Requirements for Handling Medical Radioisotopes

April 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear ...

Time April 13, 2022
arrow
Quantitative analysis of pre-treatment PSMA PET/CT in a patient undergoing treatment with ¹⁷⁷Lutetium-PSMA-617/NOX66. Post-treatment PSMA PET/CT demonstrates reduced tumor volume and PSMA intensity. Images created by S Pathmanandavel and L Emmett, St Vincent's Hospital, Sydney, Australia.
News | PET-CT
New Radionuclide Combination Therapy Safe and Effective in Metastatic Prostate Cancer Patients

April 11, 2022 — A novel nuclear medicine combination therapy has been proven safe and effective in men with heavily pre ...

Time April 11, 2022
arrow
Serial non-contrast axial chest CTs of three study participants with prior COVID-19 pneumonia.
Feature | Radiology Business | By Melinda Taschetta-Millane
Top 10: Most Read Radiology Technology Content in March 2022

Here is what you and your colleagues found to be most interesting in the field of medical imaging during the month of ...

Time March 31, 2022
arrow
With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical therapy to treat metastatic castration-resistant prostate cancer (mCRPC)—the Society of Nuclear Medicine and Molecular Imaging (SNMMI) celebrates one of the greatest success stories in nuclear medicine history.
News | Prostate Cancer
SNMMI Applauds FDA Approval of New Metastatic Prostate Cancer Treatment

March 23, 2022 — With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical ...

Time March 23, 2022
arrow
F-18 FDG PET in COVID-19–related CNS disorders: Principal components analysis of spatial covariance pattern (first row) and statistical parametric mapping analysis of metabolic group differences (second to fifth rows) in patients with COVID-19–related encephalopathy, patients with post-COVID-19 syndrome, and patients with post-COVID-19 syndrome and hyposmia compared to healthy controls (n=13). Image Created by PT Meyer, S Hellwig, G Blazhenets and JA Hosp, Medical Center – University of Freiburg, Germany.
News | Coronavirus (COVID-19)
Molecular Imaging Uncovers Effects of COVID-19 on the Brain

March 23, 2022 — A significant number of COVID-19 neurological complications— such as fatigue, headache, and cognitive ...

Time March 23, 2022
arrow
Dose tracking software allows hospitals and imaging centers to track levels of radiation used by exam type protocol.
Feature | Radiation Dose Management | By Melinda Taschetta-Millane
Measuring Radiation Dose

Dose tracking software allows hospitals and imaging centers to track levels of radiation used by exam type protocol. It ...

Time March 22, 2022
arrow
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has named Stanford Health Care and the Dana-Farber Brigham Cancer Center as its first two designated Radiopharmaceutical Therapy Centers of Excellence.
News | SNMMI
SNMMI designates first Radiopharmaceutical Therapy Centers of Excellence

March 16, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has named Stanford Health Care and the ...

Time March 16, 2022
arrow
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) deplores the recent invasion of Ukraine that has resulted in the death and injury of a large number of innocent men, women, and children—a horrifying contrast to our work to save lives and improve patient care.
News | Nuclear Imaging
Position Statement from SNMMI Regarding Situation in Ukraine

March 3, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) deplores the recent invasion of Ukraine ...

Time March 03, 2022
arrow
The Task Force members have recently observed an unusual imaging pattern on FDG PET/CT or FDG PET/MR that may be due to COVID-19 infection. 
News | Coronavirus (COVID-19)
SNMMI Task Force Reports Possible Effect of Omicron Infection on FDG PET/CT Scans

January 17, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) issued a statement on Jan. 14 regarding ...

Time January 17, 2022
arrow
Case examples of quantitative plaque analysis on coronary CT angiography and 18F-NaF PET in patients with established coronary artery disease. Hybrid CT angiography and 18F-NaF PET of coronary arteries. (A) A 70-y-old male, who presented with diffused largely noncalcified disease (middle panel in red) in the LAD and demonstrated increased 18F-NaF uptake in the LAD on PET. (B) A 59-y-old male with mild LCX atherosclerosis, who presented with a high noncalcified plaque burden (middle panel in red) on CT angio
News | PET-CT
PET/CT Artificial Intelligence Model Ideal for Predicting Risk of Future Heart Attack

January 12, 2022 — By combining information from two advanced imaging techniques with clinical data, physicians can ...

Time January 12, 2022
arrow
18F-FDG PET in patients with long-COVID syndrome. A and B: Transaxial sections of group averaged, spatially normalized 18F-FDG PET scans in patients with long-COVID syndrome (A) and control patients (B). C: The pattern expression score (PES; *adjusted for age and sex, for illustration purposes) of the previously established COVID-19-related spatial covariance pattern was not significantly different between patients with long-COVID syndrome and control patients. Boxplots (grey), as well as individual values
News | Coronavirus (COVID-19)
Molecular Imaging Suggests Long-COVID Symptoms may be Caused by Fatigue

November 1, 2021 — Long-term cognitive problems after a COVID-19 diagnosis may be a result of fatigue rather than ...

Time November 01, 2021
arrow
Determination of ER status of disease. In 59-y-old woman diagnosed with ER-positive lobular BC 2 y previously and treated with tamoxifen, ER-positive bone metastases were identified 1 y after initial diagnosis.
News | Breast Imaging
Newly Approved PET Imaging Agent Solves Clinical Dilemmas in Breast Cancer Patients
October 4, 2021 — A non-invasive, patient-friendly imaging technique can help physicians make treatment decisions for ...
Time October 04, 2021
arrow
Strategies to help guide nuclear radiology teams at various healthcare systems in 2021 and beyond
Feature | Nuclear Imaging | By Staff of the American Society of Nuclear Cardiology (ASNC)
5 Strategies for Improving Your Nuclear Radiology Lab

A year after COVID-19 turned the world upside down, the American Society of Nuclear Cardiology (ASNC) asked members how ...

Time September 16, 2021
arrow
The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient organizations, supports the introduction of H.R. 4479, the “Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021” by Congressmen Scott Peters (D-CA), Bobby Rush (D-IL), Neal Dunn (R-FL) and Greg Murphy (R-NC).
News | Nuclear Imaging
Council on Radionuclides and Radiopharmaceuticals Supports the FIND Act of 2021

August 4, 2021 — The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient ...

Time August 04, 2021
arrow
A performance evaluation of the uEXPLORER total-body PET/CT scanner showed that it exhibits ultra-high sensitivity that supports excellent spatial resolution and image quality. Given the long axial field of view (AFOV) of the uEXPLORER, study authors have proposed new, extended measurements for phantoms to characterize total-body PET imaging more appropriately. This research was published in the June issue of The Journal of Nuclear Medicine.
News | PET Imaging
Total-body PET Imaging Exceeds Industry Standards

July 10, 2021 — A performance evaluation of the uEXPLORER total-body PET/CT scanner showed that it exhibits ultra-high ...

Time July 10, 2021
arrow
The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body. Piflufolastat F-18 injection is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA and also the first commercially available PSMA PET imaging agent.
News | PET Imaging
FDA Approves First Commercially Available PSMA PET Imaging Agent for Prostate Cancer

June 28, 2021 — The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate ...

Time June 28, 2021
arrow
GE Healthcare also recently announced Xeleris V, a new virtualized, flexible AI-powered solution that provides clinicians secure access to data from anywhere – helping them make personalized care decisions and treatment recommendations that are at the heart of precision health.
News | Nuclear Imaging
GE Healthcare Advances Precision Health & Theranostics With New Products & Solutions

June 22, 2021 — At the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2021 summer conference, GE Healthcare ...

Time June 22, 2021
arrow
A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer.
News | Prostate Cancer
PSMA-Targeted Radiotracer Pinpoints Metastatic Prostate Cancer Across Anatomic Regions

June 21, 2021 — A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen ...

Time June 21, 2021
arrow
A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases in brain tau—a distinguishing characteristic of Alzheimer’s disease—before any symptoms of the disease are observed.
News | PET Imaging
New PET Tracer Detects Hallmark of Alzheimer’s Disease Years Before Symptoms Emerge

June 16, 2021 — A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases ...

Time June 16, 2021
arrow
SNMMI's Image of the Year is a detailed depiction of areas of cognitive impairment, neurological symptoms and comparison of impairment over a six-month time frame
News | PET Imaging
SNMMI Image of the Year: PET Imaging Measures Cognitive Impairment in COVID-19 Patients

June 16, 2021 — The effects of COVID-19 on the brain can be accurately measured with positron emission tomography (PET) ...

Time June 16, 2021
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now